nanoparticle albumin-bound paclitaxel

Developed for: breast cancer · gastric adenocarcinoma · malignant pancreatic neoplasm · non-small cell lung carcinoma
Investigated by: Celgene Corporation · Chinese PLA General Hospital · University of Utah · Yanqiao Zhang · Zhejiang University

Trials 4

today NCT02135822 · Ph 2 NCT02016209 · Ph 2 NCT01641783 · Ph 2 NCT01090128 · Ph 1

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT01090128	Sep 2008 → Mar 2017	breast cancer	University of Utah	Terminated	No outcome recorded
Phase 23 trials · 1 met primary
Phase 2	NCT02135822	May 2014 → May 2015	malignant pancreatic neoplasm	Chinese PLA General Hospital	Unknown	Met primary
Phase 2	NCT02016209	Jan 2014 → Dec 2015	non-small cell lung carcinoma	Zhejiang University	Unknown	No outcome recorded
Phase 2	NCT01641783	Jul 2012 → Dec 2013	gastric adenocarcinoma	Yanqiao Zhang	Unknown	No outcome recorded
Comparator or background therapy3 trials
Phase 1	NCT05382559 Background	Jun 2022 → Dec 2028 expected	cancer	Astellas Pharma Inc	Recruiting	No outcome recorded
Phase 1	NCT05157542 Background	Jun 2021 → Jun 2023	non-small cell lung carcinoma	Juan LI, MD	Unknown	No outcome recorded
Phase 1/2	NCT07444541 Background	May 2026 → Aug 2027 expected	malignant pancreatic neoplasm	Anova Innovation Limited	Not yet recruiting	No outcome recorded

Press releases naming this drug 31 releases

Date	Issuer	Release
2026-04-23	Alpha Tau Medical LTD.	Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel) alphatau.com ↗
2020-07-23	Corcept Therapeutics	Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer corcept.com ↗
2020-06-30	Corcept Therapeutics	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer corcept.com ↗
2020-06-18	Hoffmann-La Roche	Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer roche.com ↗
2020-06-17	Genentech, Inc.	Genentech’s Tecentriq in Combination With Chemotherapy (Including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer gene.com ↗
2020-03-25	BeOne Medicines	BeiGene Announces Supply Update for ABRAXANE® in China beonemedicines.com ↗
2019-12-04	Hoffmann-La Roche	FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗
2019-12-03	Genentech, Inc.	FDA Approves Genentech’s Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for The Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2019-08-29	Hoffmann-La Roche	European Commission approves Roche’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2019-06-28	Hoffmann-La Roche	CHMP recommends EU approval of Roche’s Tecentriq in combination with Abraxane as an initial treatment for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2019-05-28	Corcept Therapeutics	Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting corcept.com ↗
2019-03-11	Hoffmann-La Roche	Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane roche.com ↗
2019-03-11	Hoffmann-La Roche	FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2019-03-08	Genentech, Inc.	FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer gene.com ↗
2019-01-17	Hoffmann-La Roche	FDA accepts Roche's supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for initial treatment of metastatic non-squamous non-small cell lung cancer roche.com ↗
2019-01-16	Genentech, Inc.	FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer gene.com ↗
2018-11-13	Hoffmann-La Roche	FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer roche.com ↗
2018-11-12	Genentech, Inc.	FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Abraxane for the Initial Treatment of People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer gene.com ↗
2018-10-22	Hoffmann-La Roche	Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone roche.com ↗
2018-10-22	Genentech, Inc.	Genentech’s Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone gene.com ↗
2018-10-20	Hoffmann-La Roche	Roche's Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer roche.com ↗
2018-10-20	Genentech, Inc.	Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer gene.com ↗
2018-07-02	Hoffmann-La Roche	Phase III IMpassion130 study showed Roche's Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer roche.com ↗
2018-07-01	Genentech, Inc.	Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer gene.com ↗
2018-06-02	Hoffmann-La Roche	Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer roche.com ↗
2018-06-02	Genentech, Inc.	Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced the Risk of Disease Worsening or Death for People With Advanced Squamous Non-Small Cell Lung Cancer gene.com ↗
2018-05-29	Hoffmann-La Roche	Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone roche.com ↗
2018-05-28	Genentech, Inc.	Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone gene.com ↗
2018-03-20	Hoffmann-La Roche	Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer roche.com ↗
2018-03-19	Genentech, Inc.	Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer gene.com ↗
2016-03-16	Halozyme Therapeutics	Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine halozyme.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

Field	Value	Cited text
Known as	Nanoparticle Albumin Bound Paclitaxel	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01090128 ↗ 6 NCT07444541 ↗ NCT05157542 ↗ NCT02016209 ↗ NCT05382559 ↗ NCT01641783 ↗ NCT02135822 ↗
Known as	Abraxane	“Nab-Paclitaxel (Abraxane，ABI-007) with high effectiveness and low toxicity had been approved in breast cancer as first-line chemotherapy in many countries.” NCT01641783 ↗
Known as	Nab-Paclitaxel	“Nab-Paclitaxel (Abraxane，ABI-007) with high effectiveness and low toxicity had been approved in breast cancer as first-line chemotherapy in many countries.” NCT01641783 ↗
Route	Intravenous	“IV administered over 30 minutes.” NCT01090128 ↗